companies / neuron23-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-05 json
| total_raised | 310,000,000310.0M | ○ |
|---|---|---|
| founded | 2016 | |
| hq | South San Francisco, United States | |
| industry | unknown | |
| stage | series-b+ |
Neuron23 is a clinical-stage biotech company developing precision medicines for neurological and immunological diseases, with a focus on Parkinson's. It serves patients with genetically defined disease such as LRRK2-driven Parkinson's. Its differentiator is machine-learning-based patient selection to find people most likely to respond.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-06-01 | series-d+ | 96,500,00096.5M | null | ○ |
adobe fonts, cloudflare, cloudflare bot management, contact form 7 6.1.6, doubleclick floodlight, google analytics, google tag manager, hsts, http/3, jquery migrate 3.4.1, jsdelivr, recaptcha
| fact | status | src |
|---|---|---|
| Series D+, $96.5M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |